Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Motilal Oswal

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE: 524715 | ISIN: INE044A01036 | Industry: Pharmaceuticals
| Expensive Performer

1662.3000 -12.30 (-0.73%)

NSE Jun 03, 2025 11:18 AM

Volume: 868.9K

Sun Pharmaceutical Industries Ltd.

01 Aug 2024

1662.30

-0.73%

Specialty/DF drive earnings

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharma (SUNP) delivered better-than-expected 1QFY25 earnings, led by an improved segmental mix and lower RM costs.

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Trendlyne Marketwatch | 03 Jun 2025, 11:06AM

IPOs This Week: Prostarm, Scoda Tubes Plus Six Listings, and A New Issue

| 02 Jun 2025, 04:29PM

Change is hard, and some Indian pharma companies are embracing it better than others

| 09 Aug 2022